Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Bilzen – page 49

1 415 clinical trials in Bilzen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bilzen at a glance
1 415
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 415 trials in Bilzen

Open in trial search

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Oveporexton
  • Sponsor:Takeda Development Center Americas Inc.

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Not yet recruiting

Clinical trial of subcutaneous infliximab in patients with perianal fistulizing Crohn’s disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:CHU De Liege

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Bilzen

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management and optimization strategies for patients with chronic digestive conditions.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn

This primary care investigation evaluates various deprescribing approaches, including on-demand usage and alternative treatments, to improve long-term medication management for patients on chronic PPI therapy.

02 Primary Care Innovation

Advanced research examining optimal medication reduction strategies in the primary care setting, focusing on patient-centered approaches to decrease long-term medication use.

  • Medication Management
  • Treatment Optimization
  • Patient-Centered Care

The study compares traditional dose reduction methods with innovative approaches, including alternative therapeutic options for digestive health management.

03 Therapeutic Alternatives

Investigation into alternative treatment strategies for common digestive conditions, comparing conventional medication tapering with newer therapeutic approaches.

  • Alginate Therapy
  • On-Demand Treatment
  • Medication Reduction

Research focuses on establishing evidence-based protocols for transitioning patients from long-term PPI use to more flexible treatment regimens.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.